Clinical trials: Diabetic Peripheral Neuropathic Pain (DPN)
Neuropathic Pain, Diabetic Peripheral Neuropathy (DPN)
Oral LAT8881 in Neuropathic Pain
This is a randomised, placebo-controlled, double-blind, crossover, phase IIa study to investigate the efficacy and safety of oral LAT8881 in neuropathic pain.
- Conditions
- Neuropathic Pain, Diabetic Peripheral Neuropathy (DPN), Post Herpetic Neuralgia (PHN)
- Trial name
- NCT03865953
- Testing
- LAT8881
- Where
- 6 sites in Australia, United Kingdom
- Volunteers
- 53 people
- Sponsor
- Lateral Pharma Pty Ltd
Diabetic Peripheral Neuropathic Pain (DPN), Postherpetic Neuralgia (PHN)
Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP
Management of neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, human immunodeficiency virus-related peripheral neuropathy, and chemotherapy induced peripheral neuropathy.
- Conditions
- Diabetic Peripheral Neuropathic Pain (DPN), Postherpetic Neuralgia (PHN), HIV-related Neuropathic Pain (HIV), Chemotherapy Induced Neuropathic Pain
- Trial name
- NCT00407511
- Testing
- Pregabalin
- Where
- 11 sites in Colombia, Ecuador and 3 more
- Volunteers
- 121 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetic Peripheral Neuropathy, Neuralgia
A Study of the Efficacy and Safety of Amitriptyline/Ketamine Topical Cream in Patients With Diabetic Peripheral Neuropathy
This is a multicenter, randomized, placebo-controlled, parallel group study of EpiCept™ NP-1 Topical Cream (amitriptyline 4%/ketamine 2%) in approximately 200 patients with pain in the lower extremities due to diabetic nerve pain.
- Trial name
- NCT00476151
- Testing
- EpiCept NP-1 (4% Amitriptyline/ 2% Ketamine) Topical Cream
- Where
- India
- Volunteers
- 226 people
- Sponsor
- EpiCept Corporation
Painful Diabetic Peripheral Neuropathy
Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy
This is a randomized, double-blind, 2-arm, parallel group study of up to 274 evaluable patients designed to evaluate the safety and efficacy of the histone deacetylase 6 (HDAC6) inhibitor ricolinostat for painful DPN.
- Trial name
- NCT03176472
- Testing
- ricolinostat
- Where
- 35 sites in United States
- Volunteers
- 282 people
- Sponsor
- Regenacy Pharmaceuticals LLC
Diabetic Peripheral Neuropathy
A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the efficacy, safety, and tolerability of orally administered tapentadol extended release (ER) at dosages of 100 to 250 mg twice daily compared with placebo in patients with moderate to…
- Trial name
- NCT01041859
- Testing
- Tapentadol extended release (ER)
- Where
- 72 sites in United States, Canada and 1 more
- Volunteers
- 460 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetic Peripheral Neuropathy
Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)
The intent of this study is to treat subjects with painful Diabetic Peripheral Neuropathy (DPN) who also have pain on walking and to determine whether or not pregabalin demonstrates improvement relative to placebo on the…
- Trial name
- NCT01474772
- Testing
- Pregabalin
- Where
- 45 sites in United States, Czechia and 2 more
- Volunteers
- 217 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Neuropathy, Diabetic
A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)
The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with diabetic peripheral neuropathy(DPN)
- Trial name
- NCT00643760
- Testing
- GEn 1200mg/day, GEn 2400mg/day, GEn 3600mg/day
- Where
- 90 sites in United States
- Volunteers
- 421 people
- Sponsor
- XenoPort, Inc.
Diabetic Neuropathy, Painful
A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)
The purpose of this study is to evaluate the efficacy and safety of PF-05089771 as a monotherapy and as an add-on to pregabalin for the treatment of painful diabetic peripheral neuropathy (DPN)
- Trial name
- NCT02215252
- Testing
- PF-05089771 150 mg, Pregabalin 300 mg, PF-05089771 150 mg + Pregabalin 300 mg
- Where
- 32 sites in United States
- Volunteers
- 141 people
- Sponsor
- Pfizer
Diabetic Peripheral Neuropathic Pain
Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)
To evaluate the efficacy of NYX-2925 versus placebo in treating the neuropathic pain associated with diabetic peripheral neuropathy.
- Trial name
- NCT04146896
- Testing
- NYX-2925 50 mg
- Where
- 35 sites in United States
- Volunteers
- 228 people
- Sponsor
- Aptinyx
Diabetic Neuropathy, Painful, Diabetic Polyneuropathy
A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)
The purpose of this study is to evaluate the safety profile of orally administered tapentadol ER dosages of 100 to 250 mg twice daily in patients with chronic, painful diabetic peripheral neuropathy (DPN) over long-term exposure…
- Trial name
- NCT01063868
- Testing
- Tapentadol extended release (ER), Oxycodone controlled release (CR)
- Where
- 23 sites in United States
- Volunteers
- 47 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.